GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » BioRegenx Inc (OTCPK:BRGX) » Definitions » Cash And Cash Equivalents

BRGX (BioRegenx) Cash And Cash Equivalents : $0.07 Mil (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is BioRegenx Cash And Cash Equivalents?

BioRegenx's quarterly cash and cash equivalents declined from Mar. 2024 ($0.11 Mil) to Jun. 2024 ($0.06 Mil) but then increased from Jun. 2024 ($0.06 Mil) to Sep. 2024 ($0.07 Mil).

BioRegenx's annual cash and cash equivalents declined from Dec. 2021 ($0.02 Mil) to Dec. 2022 ($0.00 Mil) and declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).


BioRegenx Cash And Cash Equivalents Historical Data

The historical data trend for BioRegenx's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRegenx Cash And Cash Equivalents Chart

BioRegenx Annual Data
Trend Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.09 0.02 - -

BioRegenx Quarterly Data
Dec04 Mar05 Jun05 Sep05 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.11 0.06 0.07

BioRegenx Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


BioRegenx  (OTCPK:BRGX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


BioRegenx Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of BioRegenx's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


BioRegenx Business Description

Traded in Other Exchanges
N/A
Address
7407 Ziegler Road, Chattanooga, TN, USA, 37421
BioRegenx Inc is redefining health intelligence with new patented technologies and artificial intelligence. Its specialize in developing intellectual property (IP) and are engaged in regenerative biotherapeutics, anti-aging, artificial intelligence (AI) for healthcare and bioinformatics for public and private transportation. The primary focus involves acquiring or developing non-invasive medical and wellness devices capable of efficiently recording, storing, and analyzing extensive datasets.

BioRegenx Headlines

From GuruFocus

Findit Inc Announces Investor Update

By ACCESSWIRE ACCESSWIRE 07-29-2022

Findit Inc Announces New Client � Rentalz.com

By ACCESSWIRE ACCESSWIRE 07-28-2022